Key Takeaways
- • The U.S. Department of Justice declined to prosecute Campus Eye Management, a New Jersey-based management services organization, on July 29, 2026, marking the first declination under the agency's new Corporate Enforcement Policy (CEP) and voluntary self-disclosure framework.
- • Healthcare companies must distinguish between voluntary disclosure obligations to the DOJ versus reporting requirements to other government agencies (HHS-OIG, CMS) when developing compliance and self-disclosure strategies, according to legal analysis from Haynes Boone.
- • The Campus Eye Management declination establishes precedent for how the DOJ's revised enforcement posture treats healthcare fraud cases, particularly where companies engage in proactive self-disclosure under the new policy framework.
- • Legal practitioners advise healthcare organizations to carefully evaluate risk tolerance and disclosure timing, as the distinction between DOJ reporting channels and parallel agency reporting creates strategically different compliance pathways.
Summary
The U.S. Department of Justice's July 29, 2026 decision to decline prosecution of Campus Eye Management under its newly implemented Corporate Enforcement Policy represents a significant development in healthcare fraud enforcement and voluntary disclosure practices. This marks the first declination issued under the CEP framework, establishing procedural precedent for how the government will treat healthcare entities that proactively self-disclose potential compliance violations.
Campus Eye Management, a New Jersey-based management services organization, became the test case for the DOJ's revised enforcement approach. The declination signals the agency's willingness to forgo prosecution when companies meet specific conditions under the voluntary self-disclosure policy, though the full details of Campus Eye's disclosure and the underlying allegations remain subject to the parameters of the declination announcement.
According to analysis from Haynes Boone, healthcare companies evaluating their own compliance posture and disclosure obligations must carefully distinguish between reporting frameworks. Voluntary disclosure to the DOJ operates under separate criteria and timelines compared to mandatory reporting requirements imposed by other federal agencies, including the Health and Human Services Office of Inspector General (HHS-OIG) and the Centers for Medicare & Medicaid Services (CMS). This distinction carries significant strategic implications for risk assessment and disclosure timing.
The practical guidance offered by Haynes Boone emphasizes that healthcare organizations cannot treat DOJ disclosure as a substitute for other regulatory reporting obligations. Companies must weigh their specific risk profiles, the nature of potential violations, and the applicable statutes of limitations when determining whether to pursue voluntary disclosure under the CEP. The Campus Eye Management precedent provides limited but meaningful guidance on how the DOJ may evaluate good-faith disclosure efforts in the healthcare sector going forward.
Campus Eye Management, a New Jersey-based management services organization, became the test case for the DOJ's revised enforcement approach. The declination signals the agency's willingness to forgo prosecution when companies meet specific conditions under the voluntary self-disclosure policy, though the full details of Campus Eye's disclosure and the underlying allegations remain subject to the parameters of the declination announcement.
According to analysis from Haynes Boone, healthcare companies evaluating their own compliance posture and disclosure obligations must carefully distinguish between reporting frameworks. Voluntary disclosure to the DOJ operates under separate criteria and timelines compared to mandatory reporting requirements imposed by other federal agencies, including the Health and Human Services Office of Inspector General (HHS-OIG) and the Centers for Medicare & Medicaid Services (CMS). This distinction carries significant strategic implications for risk assessment and disclosure timing.
The practical guidance offered by Haynes Boone emphasizes that healthcare organizations cannot treat DOJ disclosure as a substitute for other regulatory reporting obligations. Companies must weigh their specific risk profiles, the nature of potential violations, and the applicable statutes of limitations when determining whether to pursue voluntary disclosure under the CEP. The Campus Eye Management precedent provides limited but meaningful guidance on how the DOJ may evaluate good-faith disclosure efforts in the healthcare sector going forward.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.